Kute VB, Patel HV, Varyani UT, Shah PR, Modi PR, Shah VR, Rizvi SJ, Pal BC, Shah PS, Wakhare PS, Ghodela VA, Shinde SG, Trivedi VB, Patel MH, Trivedi HL. Six end-stage renal disease patients benefited from first non-simultaneous single center 6-way kidney exchange transplantation in India. World J Nephrol 2016; 5(6): 531-537 [PMID: 27872835 DOI: 10.5527/wjn.v5.i6.531]
Corresponding Author of This Article
Dr. Vivek B Kute, MBBS, MD, FCPS, DM, Associate Professor, Department of Nephrology and Clinical Transplantation, Institute of Kidney Diseases and Research Center, Dr HL Trivedi Institute of Transplantation Sciences, B-130, Triveni, Ph-1, Ahmedabad 380016, India. drvivekkute@rediffmail.com
Research Domain of This Article
Transplantation
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Nephrol. Nov 6, 2016; 5(6): 531-537 Published online Nov 6, 2016. doi: 10.5527/wjn.v5.i6.531
Table 1 Demographic of patients
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Patient 6
Age (yr)
17
38
45
40
25
45
Gender
Male
Male
Male
Male
Male
Male
Original disease
CGN
HT
HT
ADPKD
HT
DM
ABO group
A
B
AB
AB
B
A
Dialysis
12 mo
8 mo
7 mo
18 mo
7 mo
3 mo
Weight (kg)
40
44
59
68
43
55
Original donor relation
Father
Wife
Wife
Wife
Mother
Wife
Reason for joining KPD
Sensitized
Yes
Yes
Yes
Yes
Yes
No
ABO incompatible
Yes
Time from KPD registration to find donor
2 wk
1 d
2 wk
6 mo
4 wk
1 mo
Time from donor to KT
58 d
60 d
55 d
75 d
48 d
60 d
With original donor
LCM (%)
80/80/90
5/5/7
5/0/5
80/80/90
12/7/25
FCM (MCS)
260/298
Neg/236
80/159
150/250
N/N
DSA class 1 (MFI)
A1 = 8000
No DSA
B44 = 4188
A11 = 10000
BW4 = 5000
B57 = 6200
A31 = 1100
B57 = 12645
BW4 = 12645
DSA class 2 (MFI)
DQ7 = 1600, DQ9 = 2200
DQ2 = 9000
No DSA
No DSA
DR13 = 7000
With cross donor
LCM (%)
Neg/neg/neg
15/15/20
Neg/neg
Neg/Neg/Neg
5/12/2010
Neg/Neg/Neg
FCM (MCS)
Neg/neg
Neg/200
Neg/neg
Neg/Neg
Neg/Neg
Neg/Neg
DSA class 1
No DSA
No DSA
No DSA
No DSA
No DSA
No DSA
DSA class 2
No DSA
No DSA
No DSA
No DSA
No DSA
No DSA
Desensitization
Yes
Yes
Yes
No
No
No
State
Gujarat
Rajasthan
Gujarat
Gujarat
Rajasthan
Rajasthan
Table 2 Desensitisation protocol and outcome
Patient 1
Patient 2
Patient 3
Before desensitization with original donor
LCM/DTT/AHG (%)
80/80/90
5/5/7
5/0/5
T/B FCM (MCS)
260/298
Neg/236
80/159
DSA class 1
A1 = 8000, B57 = 6200
No DSA
B44 = 4188, A31 1100
DSA class 2
DQ7 = 1600, DQ9 = 2200
DQ2 = 9000
No DSA
DP
8TPE + 8Bort/MP/IVIG + TAC/MMF
9TPE + 6Bort/MP/IVIG + R + TAC/MMF
4TPE + 4Bort/MP/IVIG + TAC/MMF
After desensitization with original donor
LCM
80/80/90
17/15/20
5/0/7
FCM
254/333
Neg/504
Neg/129
DSA class 1
A1 = 2000, B57 = 5500
No DSA
B44 = 4622, A31 = 1400
DSA class 2
DQ7 = 2000, DQ9 = 2000
DQ2 = 12000
No DSA
Side effects
Tuberculosis
Graft nephrectomy
Tuberculosis
Table 3 Human leukocyte antigen data of patients and donors
A
B
Bw
Cw
DR B1
DR B3,4,5
DQ B1
P1
2
29
44
-
4
-
7
15
4
15
51
53
4
6
D1
1
29
44
57
4
-
6
15
7
15
51
53
6
9
P2
2
33
40
44
4
6
7
15
10
15
51
-
5
6
D2
33
-
8
58
4
6
3
7
17
-
52
-
2
-
P3
2
11
35
52
4
6
12
-
4
15
51
53
6
8
D3
31
33
44
52
4
-
7
12
4
15
51
53
6
8
P4
24
32
18
35
6
-
4
7
11
15
51
52
6
7
D4
11
32
8
57
4
6
6
7
13
15
51
52
6
-
P5
24
33
8
35
6
-
4
7
17
-
52
-
2
-
D5
24
32
8
49
4
6
7
-
13
17
52
-
2
6
P6
11
24
13
56
4
6
3
4
15
17
51
52
2
5
D6
1
68
75
70
6
0
7
8
10
11
52
0
5
7
Table 4 Demographic of donor data
Donor 1
Donor 2
Donor 3
Donor 4
Donor 5
Donor 6
Age (yr)
46
38
40
38
45
35
Gender
Male
Female
Female
Female
Female
Female
Weight (kg)
44
50
50
50
60
82
ABO group
A1
B
A
B
B
B
GFR (R/L)
54/61
50/50
47/55
55/55
56/50
52/49
Creatinine (mg/dL)
0.8
0.7
0.5
0.6
0.6
0.8
Renal vessel (R/L)
2A2V/1A1V
1A1V/1A1V
1A1V/1A1V
1A1V/2A1V
1A2V/1A1V
1A1V/1A1V
LDN side
L
L
L
L
L
L
Table 5 Surgical details and outcome
Patient
1
2
3
4
5
6
WIT (s)
113
120
137
97
136
85
CIT (min)
50
150
85
136
73
60
AT (min)
31
27
24
40
25
14
UO (mL)
1100
1200
600
700
1000
950
Robotic KT
Yes
Yes
Yes
Open KT
Yes
Yes
Yes
LDN
Yes
Yes
Yes
Yes
Yes
Yes
KT date (2015)
17-Aug
21-Aug
17-Aug
18-Aug
18-Aug
7-Sep
Thymoglobulin (mg)
No
50
25
75
75
75
Creatinine (mg/dL)
0.7
0.7
1
0.7
1
1.1
Citation: Kute VB, Patel HV, Varyani UT, Shah PR, Modi PR, Shah VR, Rizvi SJ, Pal BC, Shah PS, Wakhare PS, Ghodela VA, Shinde SG, Trivedi VB, Patel MH, Trivedi HL. Six end-stage renal disease patients benefited from first non-simultaneous single center 6-way kidney exchange transplantation in India. World J Nephrol 2016; 5(6): 531-537